A Los Angeles mother of three named Marisa Peters spent years believing her health concerns were pregnancy-related before ultimately learning she had stage 3 cancer.

Her story underscores the ongoing need for better treatment options for patients with aggressive or recurring forms of the disease.

A new investigational drug may bring that relief sooner than expected, according to recent findings announced by Merck.

The experimental therapy, called sacituzumab tirumotecan or sac-TMT, demonstrated positive results in a Phase 3 clinical trial for advanced or recurrent endometrial cancer.

Here's What They're Not Telling You About Your Retirement

Merck said the drug met its primary goals of improving both overall and progression-free survival.

This achievement marks a significant step forward for the subset of patients whose disease worsened after prior treatment with platinum chemotherapy and immunotherapy.

The Phase 3 TroFuse-005 trial is the first global study to show statistically meaningful survival benefits over traditional chemotherapy options for this condition, Merck confirmed in a statement.

Researchers also said sac-TMT is currently the only antibody-drug conjugate, or ADC, to reach such outcomes in endometrial cancer.

This Could Be the Most Important Video Gun Owners Watch All Year

These targeted therapies are designed to direct cancer-fighting agents specifically to tumor cells while reducing harm to healthy cells.

The treatment is given as an intravenous infusion every two weeks. In the trial, 776 patients were randomly assigned either sac-TMT or the physician’s choice of standard chemotherapy, which included doxorubicin or paclitaxel.

Patients receiving sac-TMT showed what researchers described as “clinically meaningful improvement” when compared to those treated with standard options chosen by their doctors.

Merck reported that the study also met response rate targets and that the side effect profile resembled earlier-stage findings for this same drug.

However, the company did not release exact figures related to survival benefit, response rate, or adverse events, noting those details would appear in a future conference presentation.

Dr. Domenica Lorusso, the global lead investigator for the trial and professor at Humanitas University and Humanitas San Pio X in Milan, said the findings could mark a shift for patients who currently have few treatments left once their disease progresses.

She wrote that sac-TMT “may be able to address a critical unmet need for certain patients with advanced endometrial cancer, one of the only cancers increasing in both incidence and mortality worldwide.”

Dr. Brian Slomovitz, co-director of gynecologic oncology at Mount Sinai and a participating study investigator, echoed that need during an interview.

He noted that while other cancer deaths have declined in recent years, endometrial cancer cases and fatalities have continued to rise.

Slomovitz emphasized the importance of these results, stressing that deaths from endometrial cancer have now surpassed those from ovarian cancer in the United States. He described it as “the deadliest of all gynecologic malignancies.”

Although immunotherapy has become a new standard of care for certain patients, Slomovitz pointed out that “better treatment options” are still needed for those whose cancer returns. He said the next stage will depend on how strong and durable the survival benefit proves to be once the full data are available.

“If the full data confirm this announcement, the key questions will be the magnitude of the survival benefit and the toxicity profile,” he said.

“But an overall survival improvement in recurrent disease is a real, meaningful result for patients and their families, not just a statistical one.”

The study results, while preliminary, have generated cautious optimism among oncologists seeking a new line of defense against a cancer that continues to pose growing challenges worldwide.